Private Equity’s New Play in Medtech
Private equity buyers have jumped into the medical device sector in 2025, flush with capital and plans for revamping companies in an unforgiving, volatile macroenvironment. Blackstone and TPG’s take out of publicly traded Hologic is a high-profile example of the opportunity.
Private Equity’s New Play in Medtech
Published in MedTech Strategist
Author: Wendy Diller
Abstract:
Private equity buyers have jumped into the medical device sector in 2025, flush with capital and plans for revamping companies in an unforgiving, volatile macroenvironment. Blackstone and TPG’s take out of publicly traded Hologic is a high-profile example of the opportunity.
News
ProjectMedtech Podcast | Strategic Transactions in MedTech: Insights & Advice
Recent podcast conversation featuring Stanislav Glezer, Managing Director at Outcome Capital, on the ProjectMedtech Podcast, hosted by Duane Mancini.
Read MoreResources
Outcome Capital Life Science Market Pulse
Outcome Capital Life Science Market Pulse January 2026 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2026. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
